Covered recipient · General Payments record
DAVID BRAY
Allopathic & Osteopathic Physicians Dermatology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2019 · Entire year
$18,166.87
144 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2019 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $13,390.00 | 8 |
| Food and Beverage | $3,848.73 | 131 |
| Travel and Lodging | $928.14 | 5 |
By paying entity
PY2019 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Galderma Laboratories, L.P. | $15,657.03 | 41 |
| AbbVie, Inc. | $276.43 | 8 |
| Lilly USA, LLC | $273.17 | 9 |
| Novartis Pharmaceuticals Corporation | $270.40 | 8 |
| Celgene Corporation | $262.77 | 11 |
| UCB, Inc. | $246.87 | 8 |
| PFIZER INC. | $191.43 | 5 |
| Sun Pharmaceutical Industries Inc. | $157.51 | 7 |
| Mayne Pharma Inc. | $146.93 | 9 |
| Janssen Scientific Affairs, LLC | $123.75 | 1 |
| Janssen Biotech, Inc. | $122.19 | 10 |
| Regeneron Healthcare Solutions, Inc. | $74.11 | 4 |
| Ortho Dermatologics, a division of Bausch Health US, LLC | $50.21 | 3 |
| Almirall LLC | $43.13 | 3 |
| LEO Pharma Inc. | $40.05 | 3 |
| Hologic, LLC | $37.57 | 2 |
| Sandoz Inc. | $34.43 | 2 |
| Promius Pharma LLC | $29.00 | 1 |
| DERMIRA, INC. | $19.40 | 1 |
| Encore Dermatology Inc. | $19.05 | 1 |
| Aclaris Therapeutics, Inc. | $16.65 | 1 |
| PruGen, Inc. Pharmaceuticals | $15.95 | 2 |
| Allergan Inc. | $15.71 | 1 |
| TARO PHARMACEUTICALS USA, INC. | $15.39 | 1 |
| Amgen Inc. | $14.67 | 1 |
| Mylan Pharmaceuticals Inc. | $13.07 | 1 |
Page 3 of 3; records 101–144 of 144 matching records. This page contains 44 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
DAVID BRAY
NPI 1740266386 · CMS profile ID 260310
Allopathic & Osteopathic Physicians / Dermatology
ALEXANDRIA, VA
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 3 of 3; records 101–144 of 144 matching records. This page contains 44 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1740266386?year=2019&recipient=provider&page=3#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- DAVID BRAY, NPI 1740266386, CMS profile ID 260310. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–144 of 144 matching records. This page contains 44 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1740266386?year=2019&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
- APA 7
- IndustryPayments. (2026). DAVID BRAY, NPI 1740266386, CMS profile ID 260310. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–144 of 144 matching records. This page contains 44 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1740266386?year=2019&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
- Bluebook
- DAVID BRAY, NPI 1740266386, CMS profile ID 260310, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–144 of 144 matching records. This page contains 44 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1740266386?year=2019&recipient=provider&page=3#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2019
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30
144 matching records · $18,166.87 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 101–144 of 144.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Almirall LLC | $10.94 | 03/27/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 676649175 | CMS |
| Celgene Corporation | $24.08 | 03/26/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 672838019 | CMS |
| Mayne Pharma Inc. | $19.58 | 03/25/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 705490069 | CMS |
| Galderma Laboratories, L.P. | $16.55 | 03/21/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 687666389 | CMS |
| Sandoz Inc. | $17.25 | 03/21/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 639783815 | CMS |
| Galderma Laboratories, L.P. | $122.92 | 03/20/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 687666385 | CMS |
| Galderma Laboratories, L.P. | $47.14 | 03/20/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 687666387 | CMS |
| Celgene Corporation | $6.13 | 03/19/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 672749196 | CMS |
| Janssen Biotech, Inc. | $15.25 | 03/19/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 658343589 | CMS |
| Galderma Laboratories, L.P. | $12.32 | 03/18/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 687666383 | CMS |
| Novartis Pharmaceuticals Corporation | $15.11 | 03/12/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 658897233 | CMS |
| Ortho Dermatologics, a division of Bausch Health US, LLC | $18.97 | 03/12/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 684569595 | CMS |
| TARO PHARMACEUTICALS USA, INC. | $15.39 | 03/11/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 704148249 | CMS |
| Galderma Laboratories, L.P. | $2.95 | 03/05/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 687666381 | CMS |
| Promius Pharma LLC | $29.00 | 03/05/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 701094739 | CMS |
| Sun Pharmaceutical Industries Inc. | $20.00 | 03/04/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 704632943 | CMS |
| Janssen Scientific Affairs, LLC | $123.75 | 03/02/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 657589085 | CMS |
| Galderma Laboratories, L.P. | $99.52 | 03/01/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 687666379 | CMS |
| Lilly USA, LLC | $99.45 | 03/01/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 657783643 | CMS |
| Novartis Pharmaceuticals Corporation | $26.44 | 03/01/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 658897229 | CMS |
| Galderma Laboratories, L.P. | $135.08 | 02/28/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 687666377 | CMS |
| PFIZER INC. | $15.26 | 02/27/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 672418445 | CMS |
| Janssen Biotech, Inc. | $14.56 | 02/26/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 658343585 | CMS |
| AbbVie, Inc. | $120.28 | 02/19/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 648106647 | CMS |
| Regeneron Healthcare Solutions, Inc. | $10.96 | 02/19/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 673350036 | CMS |
| Amgen Inc. | $14.67 | 02/18/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 662294625 | CMS |
| UCB, Inc. | $123.74 | 02/13/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 688382039 | CMS |
| Galderma Laboratories, L.P. | $15.43 | 02/12/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 687666375 | CMS |
| Celgene Corporation | $5.91 | 02/07/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 672754857 | CMS |
| AbbVie, Inc. | $23.27 | 02/06/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 648106639 | CMS |
| Janssen Biotech, Inc. | $14.24 | 02/05/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 658343583 | CMS |
| Lilly USA, LLC | $21.35 | 02/04/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 657769635 | CMS |
| Mayne Pharma Inc. | $24.32 | 01/30/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 705490067 | CMS |
| Celgene Corporation | $22.14 | 01/29/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 672733467 | CMS |
| Janssen Biotech, Inc. | $14.61 | 01/29/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 658343579 | CMS |
| PruGen, Inc. Pharmaceuticals | $0.49 | 01/22/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 707765809 | CMS |
| PruGen, Inc. Pharmaceuticals | $15.46 | 01/22/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 707765815 | CMS |
| Mylan Pharmaceuticals Inc. | $13.07 | 01/16/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 694803167 | CMS |
| AbbVie, Inc. | $21.50 | 01/15/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 648106635 | CMS |
| Galderma Laboratories, L.P. | $19.59 | 01/09/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 687666373 | CMS |
| Sun Pharmaceutical Industries Inc. | $17.93 | 01/08/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 704632941 | CMS |
| Janssen Biotech, Inc. | $2.81 | 01/07/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 658343575 | CMS |
| UCB, Inc. | $13.64 | 01/07/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 688253587 | CMS |
| UCB, Inc. | $1.43 | 01/07/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 688352297 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $444,168.11 | 53 |
| PY2024 | Recipient | $1,921.15 | 12 |
| PY2024 | Principal investigator | $145,177.17 | 13 |
| PY2023 | Recipient | $9,000.00 | 1 |
| PY2023 | Principal investigator | $2,758.80 | 1 |
| PY2022 | Principal investigator | $23,214.80 | 4 |
| PY2021 | Principal investigator | $61,290.40 | 1 |
| PY2020 | Principal investigator | $6,400.00 | 3 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
53 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | SANOFI US SERVICES INC. | $4,191.00 | 12/22/2025 | Non-covered Recipient Entity Care Access Research Llc | A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of Dupilumab for the Treatment of Pruritus of Lichen Simplex Chronicus (LSC) in Adults | No dispute reported | 06/30/2026 | 1226112786 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $8,232.00 | 12/15/2025 | Non-covered Recipient Entity Care Access Research Llc | A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226112811 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $195.00 | 12/08/2025 | Non-covered Recipient Entity Care Access Research Llc | A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226112741 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $210.00 | 12/08/2025 | Non-covered Recipient Entity Care Access Research Llc | A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of Dupilumab for the Treatment of Pruritus of Lichen Simplex Chronicus (LSC) in Adults | No dispute reported | 06/30/2026 | 1226112767 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $23,700.00 | 12/08/2025 | Non-covered Recipient Entity Care Access Research Llc | A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis Who Participated in KY1005-CT05 (DRI17366) | No dispute reported | 06/30/2026 | 1226112781 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $9,435.00 | 11/17/2025 | Non-covered Recipient Entity Care Access Research Llc | A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of Dupilumab for the Treatment of Pruritus of Lichen Simplex Chronicus (LSC) in Adults | No dispute reported | 06/30/2026 | 1226112699 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $4,926.00 | 11/17/2025 | Non-covered Recipient Entity Care Access Research Llc | A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226112737 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $59,968.51 | 11/10/2025 | Non-covered Recipient Entity CARE ACCESS ALEXANDRIA | A randomized, double-blind, double-dummy, placebo-controlled, multicenter, Phase 3 study assessing the efficacy, safety, and tolerability of 2 doses of remibrutinib over a 68-week treatment period in adult patients with moderate to severe hidradenitis sup | No dispute reported | 06/30/2026 | 1190312891 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $8,463.00 | 11/10/2025 | Non-covered Recipient Entity Care Access Research Llc | A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226112723 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $750.00 | 11/04/2025 | Non-covered Recipient Entity Care Access Research Llc | A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of Dupilumab for the Treatment of Pruritus of Lichen Simplex Chronicus (LSC) in Adults | No dispute reported | 06/30/2026 | 1226112714 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $2,250.00 | 10/27/2025 | Non-covered Recipient Entity Care Access Research Llc | A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226112681 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $750.00 | 10/20/2025 | Non-covered Recipient Entity Care Access Research Llc | A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226112638 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $2,139.60 | 10/06/2025 | Non-covered Recipient Entity Care Access Research Llc | A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226112622 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $4,968.00 | 09/08/2025 | Non-covered Recipient Entity University Clinical Research Deland Accel Research Sites | A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226093680 |
| Principal investigator 1 | Incyte Corporation | $2,690.00 | 09/05/2025 | Non-covered Recipient Entity CARE ACCESS RESEARCH LLC | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240512944 |
| Principal investigator 1 | Incyte Corporation | $750.00 | 09/05/2025 | Non-covered Recipient Entity CARE ACCESS RESEARCH LLC | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240512948 |
| Principal investigator 1 | Incyte Corporation | $1,500.00 | 09/05/2025 | Non-covered Recipient Entity CARE ACCESS RESEARCH LLC | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240512952 |
| Principal investigator 1 | Incyte Corporation | $1,000.00 | 09/05/2025 | Non-covered Recipient Entity CARE ACCESS RESEARCH LLC | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240512957 |
| Principal investigator 1 | Incyte Corporation | $15,000.00 | 09/05/2025 | Non-covered Recipient Entity CARE ACCESS RESEARCH LLC | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240512961 |
| Principal investigator 1 | Incyte Corporation | $1,750.00 | 09/05/2025 | Non-covered Recipient Entity CARE ACCESS RESEARCH LLC | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240512966 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $515.00 | 08/25/2025 | Non-covered Recipient Entity Care Access Research Llc | A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226112571 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $29,235.00 | 08/18/2025 | Non-covered Recipient Entity Care Access Research Llc | A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226112533 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $62.90 | 07/14/2025 | Non-covered Recipient Entity Care Access Research Llc | A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226112413 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $275.00 | 07/14/2025 | Non-covered Recipient Entity Care Access Research Llc | A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226112419 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $470.00 | 07/07/2025 | Non-covered Recipient Entity Care Access Research Llc | A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226112335 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $85.00 | 07/07/2025 | Non-covered Recipient Entity Care Access Research Llc | A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226112341 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $4,500.00 | 07/07/2025 | Non-covered Recipient Entity Care Access Research Llc | A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226113394 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $664.90 | 07/02/2025 | Non-covered Recipient Entity Care Access Research Llc | A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226112437 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $5,809.00 | 07/02/2025 | Non-covered Recipient Entity Care Access Research Llc | A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226112473 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $425.00 | 07/02/2025 | Non-covered Recipient Entity Care Access Research Llc | A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226112479 |
| Principal investigator 1 | Genentech, Inc. | $2,501.00 | 06/25/2025 | Non-covered Recipient Entity CARE ACCESS RESEARCH LLC | VELARITE | No dispute reported | 06/30/2026 | 1211583716 |
| Principal investigator 1 | Genentech, Inc. | $1,501.00 | 06/25/2025 | Non-covered Recipient Entity CARE ACCESS RESEARCH LLC | VELARITE | No dispute reported | 06/30/2026 | 1211583725 |
| Principal investigator 1 | Genentech, Inc. | $1,750.00 | 06/25/2025 | Non-covered Recipient Entity CARE ACCESS RESEARCH LLC | VELARITE | No dispute reported | 06/30/2026 | 1211583730 |
| Principal investigator 1 | Genentech, Inc. | $16,501.00 | 06/25/2025 | Non-covered Recipient Entity CARE ACCESS RESEARCH LLC | VELARITE | No dispute reported | 06/30/2026 | 1211583741 |
| Principal investigator 1 | Genentech, Inc. | $1,001.00 | 06/25/2025 | Non-covered Recipient Entity CARE ACCESS RESEARCH LLC | VELARITE | No dispute reported | 06/30/2026 | 1211583749 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $1,000.00 | 06/09/2025 | Non-covered Recipient Entity Care Access Research Llc | A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226113325 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $17,930.50 | 05/12/2025 | Non-covered Recipient Entity Care Access Research Llc | A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226113271 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $7,920.13 | 05/05/2025 | Non-covered Recipient Entity Care Access Research Llc | A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226113232 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $9,344.50 | 04/28/2025 | Non-covered Recipient Entity Care Access Research Llc | A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226113196 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $2,250.00 | 04/28/2025 | Non-covered Recipient Entity Care Access Research Llc | A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226113237 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $9,285.00 | 04/14/2025 | Non-covered Recipient Entity Care Access Research Llc | A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226113176 |
| Principal investigator 1 | Eli Lilly and Company | $4,667.07 | 03/25/2025 | Non-covered Recipient Entity CARE ACCESS RESEARCH LLC | EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSO) | No dispute reported | 06/30/2026 | 1187878969 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $7,997.00 | 03/24/2025 | Non-covered Recipient Entity Care Access Research Llc | A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226113056 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $10,548.00 | 03/17/2025 | Non-covered Recipient Entity Care Access Research Llc | A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226112934 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $540.00 | 03/17/2025 | Non-covered Recipient Entity Care Access Research Llc | A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226112944 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $23,700.00 | 03/04/2025 | Non-covered Recipient Entity Care Access Research Llc | A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of Dupilumab for the Treatment of Pruritus of Lichen Simplex Chronicus (LSC) in Adults | No dispute reported | 06/30/2026 | 1226113018 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $705.00 | 02/18/2025 | Non-covered Recipient Entity Care Access Research Llc | A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226112874 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $375.00 | 02/18/2025 | Non-covered Recipient Entity Care Access Research Llc | A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226112887 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $375.00 | 02/18/2025 | Non-covered Recipient Entity Care Access Research Llc | A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226112950 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $12,890.00 | 02/10/2025 | Non-covered Recipient Entity Care Access Research Llc | A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226113014 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $23,300.00 | 01/21/2025 | Non-covered Recipient Entity CARE ACCESS RESEARCH | A randomized, double-blind, double-dummy, placebo-controlled, multicenter, Phase 3 study assessing the efficacy, safety, and tolerability of 2 doses of remibrutinib over a 68-week treatment period in adult patients with moderate to severe hidradenitis sup | No dispute reported | 06/30/2026 | 1190311137 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $8,418.00 | 01/21/2025 | Non-covered Recipient Entity Care Access Research Llc | A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226112905 |
| Principal investigator 1 | Eli Lilly and Company | $84,759.00 | 01/13/2025 | Non-covered Recipient Entity CARE ACCESS RESEARCH LLC | EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSO) | No dispute reported | 06/30/2026 | 1187877209 |